A shares reproduce the drug market pharmaceutical theme fund excess income is obvious.


Release time:

2014-09-28


Since September, mergers and acquisitions in the healthcare sector have occurred frequently, and the-share "medicine supplement" market has reappeared, and it has driven the increase in the net value of related theme funds.
At present, there are 18 pharmaceutical funds in the market, of which 9 are actively managed funds, namely, Fuguo Healthcare, Great Wall Healthcare, Southern Healthcare, SDIC UBS Healthcare, Bosera Healthcare, Yifangda Healthcare, Rongtong Healthcare, Huabao Xingye Pharmaceutical Biology and Tianfu Pharmaceuticals. The other nine are index funds. According to statistics, as of September 19, the above-mentioned nine actively managed health care funds have increased by an average of 6.84 per cent in the last six months, with significant excess returns relative to the market and outperforming index pharmaceutical funds.
According to the analysis, actively managed funds generally surpass index funds, mainly because actively managed funds can flexibly allocate excellent enterprises. For example, huitianfu medical and health care, as the first pharmaceutical industry fund in the industry, as of September 11 this year, the total return of huitianfu pharmaceutical since its establishment was as high as 39.04, while the CSI 300 index fell by 14.65 in the same period. From the position point of view, the fund maintains a more active strategy, the stock position mainly fluctuates between 80% and 90%, better sharing the rising market of pharmaceutical stocks. At the same time, the Shenwanzi industry of the fund's top ten heavy stocks is mainly distributed in traditional Chinese medicine and chemical preparations, indicating that the fund manager's holdings are relatively concentrated. Among them, the top three stocks, Enhua Pharmaceutical, Kunming Pharmaceutical and Laimei Pharmaceutical, have increased by 26.94, 15.9 and 13.93 respectively in the past three months.
Rich country health care has also performed well. As of September 11 this year, the CSI 300 index has risen 5.66 per cent since the fund was established, and the total return on health care in rich countries has reached 35.50 per cent over the same period. According to the second quarter report, five of the top ten stocks in the health care industry of Wells Fargo have been suspended recently, and four of them are involved in restructuring. And in the case of the stock market upward, restructuring concept stocks are easily sought after by the market.
Looking ahead, Ni Wenhao, manager of UBS Healthcare Fund, said that relative to the slow decline in capital prices, reforms and public opinion will be the main driving force for market risk appetite. With the promotion of pharmaceutical bidding in the second half of the year and the favorable policies of the industry, the pharmaceutical industry is expected to benefit from the continuation of the benign trend. As far as the choice of investment targets is concerned, it can be considered from two aspects, one is the individual stocks with the theme of reform and innovation, and the other is the growth stocks with good speed of drug bidding.
The analysis pointed out that, on the whole, under the background of continuous population aging, irreversible urbanization, and long-term continuous release of medical reform dividends, the pharmaceutical industry has stable growth prospects in the future, and investing in pharmaceutical theme funds is an important means to share the growth of the pharmaceutical industry. It can reduce risks while obtaining benefits, which is suitable for long-term allocation by ordinary investors. From the perspective of specific products, the Wells Fargo Healthcare Fund has recently suspended subscriptions due to the suspension of a number of heavy stocks. Investors may wish to turn to Huitianfu Pharmaceuticals and SDIC UBS Healthcare 2 high-performance funds to share the future development dividends of the medical industry.